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Hearing depends on glutamatergic synaptic transmission mediated by
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). AMPARs
are tetramers, where inclusion of the GluA2 subunit reduces overall channel conductance
and Ca2+ permeability. Cochlear afferent synapses between inner hair cells (IHCs) and
auditory nerve fibers (ANFs) contain the AMPAR subunits GluA2, 3, and 4. However,
the tetrameric complement of cochlear AMPAR subunits is not known. It was recently
shown in mice that chronic intracochlear delivery of IEM-1460, an antagonist selective
for GluA2-lacking AMPARs [also known as Ca2+-permeable AMPARs (CP-AMPARs)],
before, during, and after acoustic overexposure prevented both the trauma to ANF
synapses and the ensuing reduction of cochlear nerve activity in response to sound.
Surprisingly, baseline measurements of cochlear function before exposure were
unaffected by chronic intracochlear delivery of IEM-1460. This suggested that cochlear
afferent synapses contain GluA2-lacking CP-AMPARs alongside GluA2-containing
Ca2+-impermeable AMPA receptors (CI-AMPARs), and that the former can be
antagonized for protection while the latter remain conductive. Here, we investigated
hearing function in the guinea pig during acute local or systemic delivery of CP-AMPAR
antagonists. Acute intracochlear delivery of IEM-1460 or systemic delivery of IEM-1460
or IEM-1925 reduced the amplitude of the ANF compound action potential (CAP)
significantly, for all tone levels and frequencies, by > 50% without affecting CAP
thresholds or distortion product otoacoustic emissions (DPOAE). Following systemic
dosing, IEM-1460 levels in cochlear perilymph were ∼ 30% of blood levels, on average,
consistent with pharmacokinetic properties predicting permeation of the compounds
into the brain and ear. Both compounds were metabolically stable with half-lives >5 h
in vitro, and elimination half-lives in vivo of 118min (IEM-1460) and 68min (IEM-1925).
Heart rate monitoring and off-target binding assays suggest an enhanced safety profile
for IEM-1925 over IEM-1460. Compound potency on CAP reduction (IC50 ∼ 73µM
IEM-1460) was consistent with a mixture of GluA2-lacking and GluA2-containing
AMPARs. These data strongly imply that cochlear afferent synapses of the guinea
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pig contain GluA2-lacking CP-AMPARs. We propose these CP-AMPARs may be
acutely antagonized with systemic dosing, to protect from glutamate excitotoxicity,
while transmission at GluA2-containing AMPARs persists to mediate hearing during
the protection.
Keywords: Ca2+-permeable AMPA receptor, auditory nerve fiber, cochlear synapse, intracochlear drug, blood
labyrinth barrier, hearing protection, non-competitive open-channel block, IEM-1460 and IEM-1925
INTRODUCTION
To send information about sound to the brain, cochlear inner
hair cells (IHCs) excite the auditory nerve by exocytosis of
glutamate onto AMPA-type receptors at afferent ribbon synapses
(Ruel et al., 1999; Glowatzki and Fuchs, 2002; Figure 1A).
Each auditory nerve fiber (ANF, or spiral ganglion neuron)
is driven by a single, large afferent synapse where the post-
synaptic density (PSD) measured with electron microscopy is
∼ 850 nm in length, on average, and the two-dimensional
surface area ranges 0.1–1.5 µm2 [cat: Liberman, 1980; Merchan-
Perez and Liberman, 1996; mouse: Meyer et al., 2009; see
also Payne et al. (2021) in this special issue]. Glutamatergic
synapses in the brain are considerably smaller, where PSDs are
∼ 300 nm in length, on average, and most have surface area
<0.1 µm2 (Aoki et al., 2001; Qu et al., 2009; Santuy et al.,
2018). Assuming a packing density of 900 AMPA receptors per
µm2 (Momiyama et al., 2003), these cochlear synapses would
contain up to ∼1,350 receptors per afferent terminal, whereas a
typical central PSD of 0.1 µm2 would have only ∼ 90 receptors.
The PSD of the ANF supports excitatory postsynaptic currents
(EPSCs) hundreds of picoamps in amplitude in response to
each presynaptic release event. Spikes are evoked at the nearby
heminode, one EPSC at a time, at sustained rates of hundreds
of spikes per second (Sachs and Abbas, 1974; Siegel, 1992;
Rutherford et al., 2012). The spike-generating heminode of each
ANF is separated from its afferent synapse by only ∼20µm of
dendrite with a diameter <1µm (Hossain et al., 2005; Kim and
Rutherford, 2016; Figure 1B, see yellow and magenta asterisks
positioned at the ribbon synapses and heminodes, respectively).
Such tight spatial coupling between synapse and spike generator
may be essential for precise encoding of acoustic information
represented in the temporal pattern of synaptic transmission
(Rutherford and Moser, 2016). At the same time, high activity
rates such as those that occur during acoustic overexposure
may render this unmyelinated small-volume segment of the
ANF within the organ of Corti vulnerable to ionic imbalance
(Figure 1C). Immediately after a 90-min exposure to 4–8 kHz
octave band noise at 109 dB SPL, we observed some dendritic
fragmentation between the ribbon synapses in the inner spiral
plexus (ISP) and the heminodes at the habenula perforata
(HP, vertical arrowheads), consistent with synapse loss and
osmotic damage seen after synaptopathic noise exposure in
confocal and electron microscopy that can be blocked with
the glutamate receptor antagonist kynurenic acid (Robertson,
1983; Puel et al., 1998; Furman et al., 2013; Hickman et al.,
2020).
Severe acoustic trauma can kill hair cells and permanently
elevate hearing thresholds. Moderate exposures that only
temporarily elevate hearing thresholds, with no immediate loss
of hair cells, may nonetheless result in immediate damage to
or loss of afferent synapses (Kujawa and Liberman, 2009; Lin
et al., 2011). Noise-induced cochlear synaptopathy is defined
as synapse loss or dysfunction as a result of acoustic trauma
(Moser and Starr, 2016; Liberman, 2017), and is associated with
reduction in the amplitude of wave-I of the auditory brainstem
response (ABR) while otoacoustic emissions and auditory
thresholds are unchanged. The auditory nerve compound action
potential (CAP) is an analog of ABR wave-I, a metric of cochlear
output in animals including human (Relkin et al., 1995; Murnane
et al., 1998). Noise-induced cochlear synaptopathy triggers or
accelerates primary neuronal degeneration that precedes hair
cell loss and, in mice, is associated with an increased rate of
subsequent age-related permanent threshold shift (Kujawa and
Liberman, 2006; Stamataki et al., 2006). The pattern of ANF
degeneration seen in the organ of Corti and osseous spiral lamina
of animal models following synaptopathic noise exposure, and
cell death in the spiral ganglion with hair cells intact, is seen
also in human postmortem cochleae (Viana et al., 2015; Wu
et al., 2019). This noise-induced cochlear synaptopathy is a form
of excitotoxicity that appears to depend on synaptic release
of glutamate from inner hair cells (IHCs), as demonstrated in
the vesicular glutamate transporter type-3 (Vglut3) knockout
mouse (Kim et al., 2019). In the guinea pig, synaptopathic
noise exposure resulted in synaptic reorganization, impaired
temporal processing, and selective reduction in the proportion of
ANFs with the low-spontaneous rate/high-threshold phenotype
thought to be important for the encoding of suprathreshold
sounds in noisy environments (Furman et al., 2013; Shi et al.,
2013; Hickman et al., 2020). Higher doses of noise can result
in cochlear synaptopathy accompanied by immediate loss of
outer hair cells and permanent threshold shifts (Fernandez
et al., 2020). A better understanding of ANF excitability could
enable development of therapies for synaptopathy by targeting
excitotoxicity; however, the molecular mechanisms of glutamate
excitotoxicity are unclear.
AMPARs are tetramers comprised of combinations of
subunits GluA1−4 in the brain. Curiously, the mature cochlea
appears to express only GluA2−4 (Niedzielski and Wenthold,
1995; Matsubara et al., 1996; Parks, 2000; Shrestha et al., 2018). In
the adult brain, the overwhelming majority of AMPARs contain
an RNA-edited form of the GluA2 subunit rendering the channel
relatively impermeable to Ca2+, resulting in Ca2+-impermeable
AMPARs (CI-AMPARs; Sommer et al., 1991; Higuchi et al.,
Frontiers in Synaptic Neuroscience | www.frontiersin.org 2 July 2021 | Volume 13 | Article 680621
Walia et al. CP-AMPAR Antagonists for Hearing Protection
FIGURE 1 | Glutamatergic ribbon synapses and afferent fibers are vulnerable to noise exposure. (A) Square tiles (∼1 µm2 ) show 16 individual afferent ribbon
synapses from the 2nd cochlear turn of a control cochlea. The presynaptic ribbon (red) is a cytoplasmic density anchored to the presynaptic membrane of the IHC.
The main synaptic ribbon protein, Ribeye, is labeled with an antibody to CtBP2 which is the B-domain of Ribeye, and itself a nuclear transcription factor (Schmitz
et al., 2000). The ribbon is juxtaposed to a large postsynaptic array of AMPARs (green). (B) The glutamatergic ribbon synapses in the ISP (red) are ∼20µm from the
spike-generating heminodes at the HP (green). (C) Immediately after a 90-min exposure to 4–8 kHz octave band noise at 109 dB SPL. Heminodes (red) are positioned
at the habenula perforata (HP), just before ANFs become myelinated as they enter the osseous spiral lamina (OSL) toward the ganglion. Some dendrites in the ISP
appear to be severed from their heminodes at the HP (vertical arrowheads). Spike-generating heminodes and nodes on ANFs express voltage-gated Na+ channels
(anti-Pan-NaV, red). In all panels, yellow and magenta asterisks indicate positions of ribbon synapses and heminodes, respectively.
1993). AMPARs lacking edited GluA2 are called Ca2+-permeable
AMPARs (CP-AMPARs) because they have greater permeability
to Ca2+ and larger overall ionic conductance, carried mainly
by Na+ (Hollmann et al., 1991; Geiger et al., 1995). The
expression of GluA2-lacking CP-AMPARs is downregulated in
the developing brain (Pickard et al., 2000; Kumar et al., 2002;
Henley and Wilkinson, 2016). However, they persist in some
neurons of the auditory brainstem where they may be important
for fast transmission of acoustic signals (Raman et al., 1994;
Trussell, 1997; Wang et al., 1998; Gardner et al., 1999, 2001;
Lawrence and Trussell, 2000; Sugden et al., 2002; Wang and
Manis, 2005; Youssoufian et al., 2005; Lujan et al., 2019).
Some studies have implicated CP-AMPARs in mechanisms of
long-term potentiation, long-term depression, and homeostatic
scaling; however, this remains controversial as several recent
studies failed to find specific involvement of CP-AMPARs in
these processes (for review, see Henley and Wilkinson, 2016).
In any case, aberrant regulation of CP-AMPARs has been
implicated in many disorders of the central and peripheral
nervous system in which excessive activity results in oxidative
stress and neurodegeneration (Cull-Candy et al., 2006; Kwak and
Weiss, 2006; Liu and Zukin, 2007; Weiss, 2011).
The extent to which CP-AMPARs exist in the ear is not
entirely clear. They may be downregulated over development
in the rat cochlea (Eybalin et al., 2004), as in the brain.
In rodents, cochlear afferent synapses are typically quantified
with confocal microscopy by counting the juxtaposition of
immunohistofluorescence of the presynaptic ribbon paired with
postsynaptic GluA2 (Khimich et al., 2005; Meyer et al., 2009;
Liberman et al., 2011; Figure 1). All cochlear afferent synapses
appear to express GluA2, leading to the supposition that CP-
AMPARs are not present in the cochlea, if cochlear GluA2
RNA is edited as in the brain. Although GluA2 may be present
at every synapse, each cochlear afferent synapse is thought to
contain hundreds to thousands of AMPARs. We hypothesize
that a subset of the AMPARs at each synapse lack GluA2 in
the tetramer. High-resolution confocal microscopy of cochlear
afferent synapses has suggested GluA2-lacking nanodomains
within the large PSDs on ANFs (Sebe et al., 2017; Hu et al.,
2020). Moreover, chronic local delivery of an antagonist (IEM-
1460), selective for CP-AMPARs at low µM concentrations,
prevented noise-induced glutamate excitotoxicity in the mouse
cochlea (Hu et al., 2020). This study suggested GluA2-lacking
CP-AMPARs could be therapeutic targets at mature cochlear
afferent synapses; however, the concentration of IEM-1460 in
perilymph was not measured, thus the selectivity of the blockade
was uncertain.
IEM-1460 and IEM-1925 are dicationic compounds that
are non-competitive open-channel blockers selective for the
pore of GluA2-lacking CP-AMPARs (Magazanik et al., 1997;
Tikhonov et al., 2000). A non-competitive blocking mechanism
should not interfere with glutamate binding to the ligand-
binding domain of AMPA, NMDA, kainate, or metabotropic
glutamate receptors, thus reducing the potential for off-target
effects at other glutamate receptors. Open-channel blockers
are use-dependent, requiring channel activation for access
to the pore region of the transmembrane domain, thus the
blocking effect develops exclusively in the presence of an agonist
(Tikhonova et al., 2008; Twomey et al., 2018). Here, in guinea
pig, with intracochlear perfusion of defined concentrations of the
compound in artificial perilymph, we measured the immediate
concentration-dependent effects of IEM-1460 on ANF activity.
Further, with systemic dosing in vivo and with cell-based assays
we assessed pharmacokinetics, metabolic stability, and toxicity of




This study utilized 21 NIH-strain, pigmented guinea pigs
weighing from 400 to 650 g, in accordance with policies and
protocols approved by the Institutional Animal Care and Use
Committee at Washington University in St. Louis (20180133,
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20190035). Animals were anesthetized with intraperitoneal (IP)
injection of 100 mg/kg sodium thiobutabarbital (Inactin, Sigma,
St. Louis, MO). Once anesthetized, the fur from the head
and neck was shaved and a tracheal cannula was placed.
The animal was maintained on 0.8–1.2% isoflurane in oxygen
using a mechanical ventilator. The ventilator’s tidal volume was
adjusted to maintain a 5% end-tidal CO2 which was monitored
with a CapnoTrue AMP (Bluepoint Medical, Zevenaar, The
Netherlands). Body temperature was maintained at 38 degrees C
with a DC-powered heating blanket-rectal thermometer (Model
50-7079; Harvard Apparatus). Heart rate and oxygen saturation
were monitored with a pulse oximeter (Surgivet, Waukesha,
WI). The auditory bulla was exposed ventrally for placement
of recording electrodes. The jugular vein was cannulated
to maintain hydration with 0.5mL per hour of Lactated
Ringer’s solution. To prevent middle ear muscle contractions,
vecuronium bromide (0.2 mg/kg) was administered immediately
prior to data collection and every 1.5 h thereafter.
Immunostaining of Cochlear Synapses
Following cardiac perfusion of 4% PFA in 0.1M phosphate buffer
and cervical dislocation, the temporal bone was immediately
harvested, and the cochlea was isolated. Each cochlea was
post-fixed for 20min at 4◦C in a dish with 4% PFA, where a
small fenestration was made in the round window, oval window,
and the apex of each cochlea to gently flush with 1mL of
fixative. Each cochlea was then decalcified in 10% EDTA at
room temperature for 6 h, exchanging EDTA every 2 h. The
decalcified outer bone was removed to reveal the underlying
cochlear spiral. Small pieces of cochlear turns were placed in
buffer overnight at 4◦C in Triton X-100 with donkey serum. The
following primary antibodies were used: anti-C-terminal binding
protein-2 to label presynaptic ribbons (CtBP2 mouse IgG1,
1:300, BD Biosciences #612044, RRID AB_399431); anti-AMPA
receptor subunit-3 to label post-synaptic densities (GluA3 goat,
1:200, SCBT, RRID AB_2113895); anti-myosin VII-A to label
inner hair cell cytoplasm (Myo7a rabbit, 1:400, Fisher Scientific
#NC0165634, RRID AB_2553946); anti-vesicular glutamate
transporter-3 (Vglut3 goat, 1:400, SCBT RRID AB_2187701);
anti-adenosine triphosphate-dependent sodium/potassium
exchanger-α3 to label neuronal membranes (NaKATPase mouse
IgG1, Life TechMA3-915, RRID AB_2274447); anti-pan voltage-
gated sodium channel-α1 to label heminodes and nodes (NaV1
mouse IgG2a, AB Inc. 75-405, RRID AB_2314861). The primary
antibodies were labeled with species-appropriate secondary
antibodies conjugated to Alexa Fluor 488, 555, or 647 (1:200, Life
Technologies Corp.). Digital images were obtained using a Zeiss
LSM700 confocal microscope with 63× oil immersion objective,
1.4N.A., with pixel size of 50–100 nm in X and Y, and Z step size
of 0.3–0.5 µm.
Stimulus Generation and Recording for
Experiments With Intracochlear Drug
Delivery
The head was stabilized in a head-holder with a solid ear bar
on the left side and hollow ear bar on the right side, a bite bar,
and a snout clamp. Sound calibration, stimulus generation, and
recording methods have been detailed previously (Lichtenhan
et al., 2016a, 2017). Briefly, cochlear function measurements
were made using MATLAB software (The MathWorks, Natick,
MA) and the software utility Playrec. The stimulus was
first generated in MATLAB, digitized at 96 kHz, presented
to a 24-bit sound card (RME: Fireface802; Sweetwater, Fort
Wayne, IN), and then routed to an acoustic probe system
(ER-10X; Etymotic Research, Fort Wayne, IN). The ER-10X
microphone was calibrated using a reference microphone
(1/8” GRAS type 40P) and a custom-made coupling system
was used for setting stimulus levels. Sound was presented
through the hollow ear bar on the right side via the ER-10X
microphone probe.
Cochlear output was recorded as a field potential between
a Ag/AgCl ball electrode in the cochlear round window niche
and a platinum needle electrode at the vertex of the cranium.
Responses to 20 tone bursts (10 with reversed polarity) were
averaged for each CAP measurement at a given frequency
and level. The CAP audiogram was measured (1–22 kHz, 1/4
octave steps) at the beginning and end of the experiment to
determine CAP threshold as a function of tone-burst frequency.
Prior to and immediately after IEM-1460 perfusions via the
apical cochlear fenestration (see below), CAPs were evoked by
tone bursts at selected frequencies and levels. Measurements
were repeated at 1- to 2-min intervals to monitor cochlear
output and to ensure response stationarity for at least 25min
prior to drug delivery. Data with baseline changes >20%
were excluded. The round window niche was monitored for
accumulation of fluid.
Stimulus Generation and Recording for
Experiments With Systemic Drug Delivery
As described for local delivery, cochlear output was measured
similarly for systemic delivery of IEM-1460 and IEM-1925.
Complete details have been previously published (Salt et al.,
2013). Briefly, acoustic tone bursts were applied in a closed
sound system. The plastic extension tube of the acoustic
assembly (Etymotic Research, ER-10C) was coupled to the
end of the hollow ear bar with the tube tip positioned
∼1.5mm from the tympanic membrane. Stimulus generation
and data collection were performed with Tucker Davis System
3 hardware controlled by a custom written program (Microsoft
Visual Basic). Stimulus waveforms were routed through a
programmable Tucker Davis PA5 attenuator andHB7 headphone
amplifier. Stimuli were calibrated from 0.125 to 26 kHz in
1/4 octave steps. A CAP audiogram was obtained at the
beginning and end of the experiment. Up to 60min of baseline
audiometric data were obtained prior to drug delivery. Data
with baseline changes >20% were excluded. A 13-level tone
probe series, at selected frequencies, was repeated at 2-min
intervals. Distortion product otoacoustic emissions (DPOAEs)
were measured using an ER10C probe system. The two primary
tone frequencies were set at 6 kHz (f1) and 7.4 kHz (f2), for
a f2/f1-ratio of 1.23, with levels of 65 dB SPL (L1) and
55 dB SPL (L2).
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Electrophysiological Data Analysis and
Statistics
At each probe frequency, CAP peak-to-peak amplitudes were
measured from the first trough (N1) to the first peak (P1).
Latencies were measured to the trough of N1. Cochlear output
was compared before and after intraperitoneal drug delivery. The
data were tested for normality using a Kolmogorov-Smirnov test.
For CAP amplitude and latency, significance was assessed with
the Mann-Whitney U-test. The Wilcoxon signed rank test was
used to assess CAP threshold. Friedman test was used to compare
concentrations of drug between perilymph and CSF. A p < 0.05
was considered statistically significant. A Bonferroni correction
was used when performing multiple comparison testing. All
statistical tests were performed with IBM SPSS Statistics Version
27 (SPSS Inc., Chicago, IL, United States).
Intracochlear Drug Delivery
The method of apical intracochlear drug delivery has previously
been well-detailed (Lichtenhan et al., 2016a). IEM-1460 or kainic
acid (KA) in artificial perilymph (in mM: 127.5 NaCl, 3.5 KCl,
25 NaHCO3, 1.3 CaCl2, 1.2 MgCl2, 0.75 NaH2PO4, and 11
glucose) was injected into scala tympani from a glass pipette
that was sealed into the cochlear apex. We refer to this method,
below, as the apical perfusion technique. To insert the injection
pipette, the mucosa on the bone of the fourth cochlear turn was
removed with a moist, cotton wrapped applicator. A thin layer
of cyanoacrylate glue was then applied to the dried area (no.
101; Permabond) followed by a layer two-part silicone elastomer
to make a hydrophobic cup-shaped dike (Kwik-Cast; World
Precision Instruments). A fenestration was then made through
the cup-shaped elastomer (∼100–150µm) with a 30◦ pick (Storz
N170580, 1/3mm 30◦ oval window pick, Bausch & Lomb
Surgical, St. Louis, MO, USA). The size of the fenestration was
just large enough to insert a glass pipette (∼50µm diameter tip)
which was then sealed into the fenestration with the application
of additional cyanoacrylate glue to form a seal and prevent
the possible leakage of perilymph. Solutions in the injection
pipette were programmatically driven by a 50 or 100 µL gastight
syringe (1710TLL; Hamilton Syringe) mounted on a computer-
controlled ultrapump (UMP3, World Precision Instruments,
Sarasota, FL). Injection of drug solution at a rate of 500 nL/min
for 15min drives drug solution toward the cochlear aqueduct,
filling scala tympani from the apex to the base, controlling drug
concentration by minimizing physiological dilution. Here, the
apical perfusion technique was applied for 15min, with the scala
tympani being fully loaded within 12min. Response waveforms
were recorded immediately prior to apical drug perfusion to
establish a baseline, throughout perfusion which took 6min,
and then immediately after perfusion, from a round window
electrode. Cochleae were prepared for fixation immediately
following perfusion.
Intraperitoneal Drug Delivery
After at least 30min of baseline data, 1mL of Lactated Ringer’s
was injected into the peritoneal space of the guinea pig as a
vehicle control. Then, 13.5 mg/kg IEM-1460 or 8 mg/kg IEM-
1925 in Lactated Ringer’s was injected into the peritoneal space
of the guinea pig. The entire experiment took ∼3 h to complete:
1 h for anesthetic induction and surgery, 30min for sound
calibration and CAP threshold measurements, and 2 h for drug
delivery, DPOAE and CAP measurements. After collection of
perilymph and CSF, the animal was euthanized via saturated KCl
delivered directly into the jugular vein.
Collection of Blood, Perilymph, and CSF
After IP Drug Injection
General surgical scissors were used to clip the toenail at a 45◦
angle to collect blood with a premarked glass capillary tube
during the baseline period and after drug injection. The exact
volume was determined by measurement of the fluid meniscus
in a calibrated capillary tube. Sampling of perilymph from the
cochlear apex was performed to measure drug concentrations
once the CAP amplitude had decreased, suggesting that there
had been drug penetration within the cochlea. Complete details
used to perform apical fluid sampling are presented elsewhere
and are only briefly provided here (Mynatt et al., 2006). Similar to
the apical cochlear fenestration used to deliver drugs (described
above), the mucosa on the cochlea was cleared from two apical
turns using a small cotton swab, and the bone at the apex was
allowed to dry. A droplet of thin cyanoacrylate adhesive was
applied and cup formed over the apex with silicone adhesive.
A small perforation (50–100µm diameter) was then made in
the bone over scala vestibuli at the apex using a 30◦ pick.
Upon perforation, fluid immediately started emerging, driven
by intralabyrinthine pressure from CSF, and formed a bead
within the hydrophobic silicone cup. A calibrated 5 µL capillary
micropipette (VWR #5342-706, S. Plainfield, NJ) was held by
hand in contact with the fluid at the apex, so that fluid was drawn
into the capillary in ∼30 s. The exact volume was determined by
measurement of the fluid meniscus. Perilymph from the opposite
ear was sampled prior to euthanizing the animal, then ∼2 µL of
CSF was aspirated by inserting a micropipette through the dura
mater into the cisterna magna. After the fluid meniscus from the
capillary tube was measured, the capillary tube was then flushed
with 25.0 µL 50:50 methanol-water solvent to ensure that all the
sample was collected.
Liquid Chromatography and Mass
Spectroscopy (LC/MS)
The concentration of IEM-1460 in perilymph, blood, and CSF
was analyzed using LC-MS (Confluence Life Sciences, St. Louis,
MO). LC-MS-grade acetonitrile, LC-grade methanol, formic
acid, sodium hydroxide 0.1M, perfluoroheptanoic acid, formic
acid, and hydrochloric acid were purchased from Sigma-Aldrich
(USA). Deionized water (R > 18 M/cm, TOC < 10 ppb)
was used throughout all these experiments. IEM-1460 and IEM-
1925 were purchased from Tocris Bioscience (Bristol, UK). A
10mM stock solution was made for both IEM-1460 and IEM-
1925 in 50% aqueous methanol. For calibration of the specific
compound concentration in the tested matrix (i.e., plasma or
CSF/perilymph), a set of standard solutions were prepared
by diluting concentrated stock solutions with 50% aqueous
methanol into guinea pig plasma matrix or artificial perilymph
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(in mM: 127.5 NaCl, 3.5 KCl, 25 NaHCO3, 1.3 CaCl2, 1.2 MgCl2,
0.75 NaH2PO4, and 11 glucose) to have a set of standards
from 1 to 300 ng/mL. Figure 2 shows the calibration curves
and chromatograms in both blood and CSF for compounds
IEM-1460 and IEM-1925. Calibration standard samples using
verapamil were prepared for each batch of samples ranging from
1 to 300 ng/mL and injected at both the beginning and end of
the sample sequence. The methodology for LC-MS for blood
has previously been described (Da Silva et al., 2016; Guiraud
et al., 2017). Separation and analysis were performed on a LC
instrument (Exion LC AD, AB SCIEX, USA) coupled to a Sciex
QTRAP5500 with TurboV Ion Source (SCIEX, Concord, ON,
Canada) equipped with a heated electrospray ionization (H-
ESI) source. Chromatographic separation was obtained using a
gradient elution on a reversed-phase Kinetex F5 (Phenomenex,
Aschaffenburg, Germany) column (2.1 × 50mm), packed with
1.7µm diameter particles. The injection volume was 5 µL, and
the total run time for this analysis was 6 min.
Immediately after collection of the guinea pig samples of
blood, CSF, and perilymph obtained following IP injection, the
samples were diluted in 25 µL of 50:50 methanol-water solvent
and were subsequently stored at−80◦C. Prior to LC/MS analysis,
perilymph, blood, and CSF samples were thawed and vortexed
for 2min. Approximately 25 µL of the diluted sample was
transferred into a 0.5mL microcentrifuge tube. The tube was
then placed into a multitube vortexer for 15min at 1,350 rpm
at 4◦C and then centrifuged at 14,800 rpm for 10min. The
supernatants were then pipetted and filtered through a 0.22µm
filter and placed into a 96-well plate for LC-MS analysis. To
assess the matrix effects of the column, a sample containing
the internal standard analyte added to the extracted matrix and
another sample containing the internal standard analyte in the
mobile phase solvent were used. The same concentration of the
internal standard analyte was used in both samples. Matrix effect
values were calculated by (%)= B/A ∗ 100 (A=mean of external
solution peak area, B = post-extraction sample peak area). The
LC/MS procedure was validated using specificity and selectivity,
linearity, trueness, precision, recovery, limit of detection (LOD),
and limit of quantification (LOQ). Themass spectrum profile and
retention time of pure standards were used to assess specificity
and selectivity by comparing this value to unspiked CSF and
plasma samples. LOD was assessed by ensuring that the samples
were at least three times higher than the signal-to-noise ratio
(SNR) and LOQ was assessed by ensuring that analytes were 10
times higher than the SNR. Calibration curves were constructed
for each concentration level by calculating the chromatographic
peak area ratio of the analyte in comparison to the internal
standard area. Repeatability was assessed by spiking the plasma
and perilymph standard solutions with low, medium, and high
levels of IEM. Six replicates were performed for each standard
solution by the same operator on three separate occasions.
In vitro Microsomal Stability Assay
The stability of IEM-1460 in the presence of guinea pig
liver microsomes (BioIVT, PN: X008070) or IEM-1925 in
the presence of human (BioIVT, PN: M00101), mouse, or
guinea pig liver microsomes was evaluated (Paraza Pharma,
Inc., Montreal, Quebec, Canada). Both IEM-1925 and IEM-
1460 were incubated with microsomes at 37◦C for a total of
45min. Working solutions were prepared in 100mM potassium
phosphate buffer and the final reaction was performed at pH 7.4
in 100mM potassium phosphate buffer containing 0.5 mg/mL
liver microsomal protein. Phase I metabolism was assessed by
adding NADPH to a final concentration of 1mM and collecting
samples at time points 0, 5, 15, 30, and 45min. All collected
samples were quenched 1:1 with ice-cold stop solution (1µM
labetalol and 1µM glyburide in acetonitrile) and centrifuged
to remove precipitated protein. Resulting supernatants were
further diluted 5-fold with water. Samples were analyzed by
LC-MS/MS using a Thermo Vanquish UPLC and a Thermo
Quantis triple quadrupole mass spectrometer. Analytes were
injected into a Phenyl column and chromatographed using a
reverse phase gradient with 0.1% formic acid in water and
0.1% formic acid in 20/80 Isopropanol/Acetonitrile mobile
phases. Reference compounds were also assessed to ensure
accuracy and precision of experimental protocol: imipramine
and verapamil for human liver microsomes, diphenhydramine
and verapamil for mouse liver microsomes, and warfarin and
verapamil for guinea pig liver microsomes. Calculations for half-
life, in-vitro clearance, and percentage of hepatic blood flow
were performed using Microsoft Excel. Half-life was determined
from a plot of the natural logarithm of the peak area ratio
(remaining compound peak area/internal standard peak area)
against time.
Radioligand Binding Assays
Binding assays were conducted to evaluate the affinity of
test compounds IEM-1460 and IEM-1925 (Eurofins Scientific,
Inc.) for 15 targets: the human alpha-1 adrenergic (A1)
receptor, histaminergic (H)-2 and−3 receptors, and muscarinic
acetylcholine receptors-1 to−5 in transfected CHO cells by
radioligand binding. The neuronal α4β2 and neuronal α7
cholinergic acetylcholine receptors were tested in transfected SH-
SY5Y cells. The histaminergic-1 and−4 receptors were tested in
transfected HEK-293 cells. Ion channel testing for AMPA and
N-methyl-D-aspartate (NMDA) was performed in cells from the
rat cerebral cortex. For alpha-1 adrenergic receptor (Townsend-
Nicholson and Schofield, 1994), cell membrane homogenates
(∼23 µg protein) were incubated for 1 h at 37◦C with 1 nM
of [3H]DPCPX in the absence or presence of IEM-1460 or
IEM-1925 in a buffer containing the following in mM: 25
HEPES/KOH (pH 7.0), 100 NaCl, 1.5 CaCl2, 1 MgSO4, and 0.2
g/L 1.10 phenanthroline and 0.1% BSA. Non-specific binding
was determined in the presence of 1µM of DCPX. Following
incubation, the samples were filtered rapidly under vacuum
through glass fiber filters (GF/B, Packard), presoaked with 0.3%
PEI and rinsed several times with ice-cold 50mMTris-HCl using
a 96-sample cell harvester (Unifilter, Packard). The filters were
dried and then counted for radioactivity in a scintillation counter
(Topcount, Packard) using a scintillation cocktail (Microscint
0, Packard). The results are expressed as a percent inhibition
of the control radioligand specific binding: 100-[(measured
specific binding)/(control specific binding) × 100]. IEM-1460
or IEM-1925 was tested at 1µM to determine the percent
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FIGURE 2 | LC/MS calibration curves for IEM-1925 and IEM-1460. (A) The LC/MS calibration curve showing the relative area of IEM-1925 to internal standard
(verapamil) in blood is plotted against IEM-1925 concentration. Replicates for each concentration were obtained with duplicate injections. The 1 ng/mL standard in
blood chromatogram with S/N ∼ 3.1 is shown in the inset that eluted at 1.73min. (B) Similarly, LC/MS calibration curve showing IEM-1925 in CSF matrix is plotted
against the internal standard. The 1 ng/mL standard in CSF with S/N ∼3.2 is shown in the inset eluting at 1.74min. (C) IEM-1460 calibration curve in blood with inset
showing 1 ng/mL IEM-1460 in blood with S/N ∼3.8 eluting at 1.78min. (D) IEM-1460 calibration curve in CSF with inset showing 1 ng/mL IEM-1460 in CSF with S/N
∼ 4.2 eluting at 1.78min.
inhibition of binding when compared to the reference compound
(a known agonist) for each specific receptor. These steps were
repeated for H1 (Smit et al., 1996), H2 (Leurs et al., 1994),
H3 (Lovenberg et al., 1999), H4 (Liu et al., 2001), M1-2 (Dörje
et al., 1991), M3 (Peralta et al., 1987), M4-5 (Dörje et al., 1991),
N-α4β2 (Gopalakrishnan et al., 1996), N-α7 (Sharples et al.,
2000), AMPA (Murphy et al., 1987), and NMDA (Sills et al.,
1991) receptors.
RESULTS
Destruction of Ribbon Synapses and
Afferent Terminals With Intracochlear
Perfusion of Glutamate Receptor
Antagonist
Previous studies perfused the cochlea with glutamate receptor
agonists and antagonists through cochleostomy in the basal
turn of the cochlea (Puel et al., 1994). To demonstrate the
effectiveness of our apical injection technique to target the
entire cochlea from apex to base, we perfused the guinea
pig cochlea with artificial perilymph with or without the
AMPA/kainate receptor agonist kainic acid (KA), followed by
immunohistofluorescence and confocal microscopy (Figure 3).
Perfusion of artificial perilymph into scala tympani from the
cochlear apex resulted in images like those taken from naïve
controls, showing dense innervation in the neuropil of the organ
of Corti under IHCs in the ISP (Figures 3A–C, see yellow
asterisks). Perfusion of artificial perilymph containing 2mM KA
resulted in a void of innervation in the ISP and ribbon synapse
disintegration (Figures 3D–F, see yellow asterisks), consistent
with terminal swelling and dendrite retraction seen with chemical
lesion in electron microscopy (Puel et al., 1994). Disintegration
of synapses in turn one (Figure 3F) confirms that the apical
injection method perfuses the scala tympani all the way to the
base of the cochlea.
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FIGURE 3 | Apical cochlear perfusion of kainic acid lesions ANF dendrites throughout the cochlear spiral. (A,B) Whole-mount preparation from the apical turn (turn
four) of guinea pig cochlea. Inner hair cells (IHCs) are labeled with anti-Vglut3 (blue); Type-I auditory nerve fibers innervating IHCs in the inner spiral plexus (ISP) and
tunnel-crossing medial olivocochlear efferent neurons are labeled with anti-Na+/K+-ATPase (green). In all panels, yellow asterisk indicates location of ribbon synapses
in the ISP. (C) Whole-mount preparation from the basal turn (turn one). In control samples, presynaptic ribbons (anti-CtBP2, red) of IHCs (anti-Myosin7a, blue) are
paired with postsynaptic AMPA receptors (anti-GluA3, green) in the ISP. Anti-CtBP2 also labels cell nuclei. Perfusion of artificial perilymph into scala tympani from the
cochlear apex resulted in images like those taken from naïve controls, showing dense innervation in the neuropil of the organ of Corti under IHCs (in the inner spiral
plexus, ISP). (D–F) Disintegration of synapses from the cochlear apex (turn four) to the base (turn one) confirms the apical perfusion solution accessed the scala
tympani all the way down the length of the cochlea.
Dose-Dependent Reduction of Auditory
Nerve Activity With Intracochlear Perfusion
of Selective CP-AMPAR Antagonist
IEM-1460
Previously, we blocked noise-induced synapse loss and
concomitant reduction of ABR wave-I with chronic intracochlear
delivery of IEM-1460 via a cannula inserted through the round
window, connected to an osmotic minipump implanted in
the middle ear of mice (Hu et al., 2020). The concentration of
IEM-1460 eluted from the minipump was 500µM; however,
the intracochlear concentration of the diluted compound
was not known. At high concentration, IEM-1460 will block
GluA2-lacking and GluA2-containing AMPARs (IC50 =
∼500–1,100µM on GluA2-containing AMPARs) (Magazanik
et al., 1997; Buldakova et al., 1999). At low concentration,
it is selective for GluA2-lacking receptors. Cells expressing
GluA2-lacking AMPARs exhibit high sensitivity to IEM-1460
(IC50 = ∼1–3µM). Cells expressing a combination of CP-
AMPARs and Ca2+-impermeable receptors (CI-AMPARs) have
intermediate sensitivity.
Auditory nerve activity is triggered by the activation of
AMPARs by glutamate. Thus, to interrogate AMPAR subunit
composition in the guinea pig, we asked if IEM-1460 could
reduce sound-evoked auditory nerve activity at concentrations
consistent with antagonism of GluA2-lacking CP-AMPARs. First,
we used the apical perfusion technique to test the effect of
different concentrations of IEM-1460 on cochlear responses to
sound. When a tone burst is applied to the ear, synchronous
exocytosis of glutamate from IHC ribbon synapses triggers
synchronous depolarization of ANFs through activation of
AMPARs, triggering action potentials. The amplitude of the
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FIGURE 4 | Auditory nerve compound action potential (CAP) measurements before and after cochlear perfusion with IEM-1460. (A) IEM-1460 dose-response
inhibition curve shows relative reduction in CAP amplitude with increasing concentration of IEM-1460 varying from 0.1 to 4,000µM (N = 6 female guinea pigs,
8–9-weeks-old). Probe level was 80 dB SPL. Fractional reduction from baseline was averaged for responses to 2 and 16 kHz tones. IC50 = ∼ 73µM. (B) CAP
thresholds across frequencies before and after perfusion of 100µM IEM-1460 in artificial perilymph into scala tympani from an injection pipette sealed to the cochlear
apex. C) CAP waveforms in response to 70 dB SPL tone bursts at 2, 8, and 16 kHz. Gray traces were recorded before perfusion, and black traces were recorded
after perfusion of 100µM IEM-1460 in artificial perilymph. (D) Baseline normalized CAP amplitudes (N1-P1, left) and N1 latencies (right) as a function of probe level for
the three probe frequencies. Perfusion with 100µM IEM-1460 reduced CAP amplitude and increased CAP latency.
auditory nerve field potential, the CAP, reflects the number of
contributing ANFs (Earl and Chertoff, 2010).
At 10µM IEM-1460, the amplitude of the tone-evoked CAP
was reduced by ∼25%. With increasing concentration, the CAP
progressively decreased. For 80 dB SPL tones at 2 and 16 kHz, on
average, the CAP amplitude was reduced by ∼55% with 100µM
IEM-1460 in the perfusion pipette (Figure 4A). Relative to the
pre-drug baseline recording, the reduction in CAP amplitude
with 100µM IEM-1460 was greater for lower-frequency tones
(∼ 60% at 2 kHz) than for higher-frequency tones (∼30% at
16 kHz) (Figures 4C,D, left). Although we don’t know the reason
for this difference, it would be expected if either the mechanical
disturbance of the injection was greater or if the IEM-1460
concentration was greater near the perfusion pipette in the
apex, and/or if AMPARs of apical ANFs had less GluA2 and
thus greater Ca2+-permeability. Relative to pre-drug measures,
CAP latencies increased by ∼10% (additional delay of ∼0.3ms)
across tone levels and frequencies in the presence of 100µM
IEM-1460 (Figure 4D, right). There was a trend toward longer
relative latency shifts in response to higher-level tones than
lower-level tones.
The dose-response inhibition plot for relative CAP reduction
with increasing concentration of IEM-1460 was fit with a
Boltzmann sigmoidal equation to obtain the concentration for
a 50% CAP reduction (IC50) of 73µM. Thus, at ∼73µM
IEM-1460, the AMPAR-mediated excitatory postsynaptic current
(EPSC) of the guinea pig cochlea was antagonized enough to
reduce the amplitude of the auditory nerve field potential by 50%.
Assuming linear summation, this suggests that ∼ 50% of ANFs
failed to spike at sound onset under this condition. We note this
50% reduction in the CAP does not imply a 50% reduction of the
EPSC (see Discussion).
For a given tone frequency, the sound level needed to
evoke a 10 µV CAP waveform amplitude is considered the
“threshold level” (dB SPL). CAP thresholds correlate very closely
with behavioral thresholds for auditory perception in rodents
(Dallos et al., 1978; Lichtenhan et al., 2013). With 100µM
IEM-1460, changes in CAP threshold across frequencies from
1 to 20 kHz were very small (<5 dB SPL; Figure 4B) and
within test-retest variability, despite considerable reduction in
CAP amplitudes at 2, 8, and 16 kHz (Figures 4C,D). For tones
at levels within 5–10 dB of threshold, baseline-normalized
CAP amplitude reduction and baseline-normalized CAP latency
increase tended to be smaller than for tones at 45–50 dB super-
threshold levels (Figure 4D), suggesting that responses to low-
level tones may have been inhibited less than responses to
high-level tones.
Reduction of Auditory Nerve Activity With
Systemic Delivery of IEM-1460
Next, we asked if IEM-1460 would produce similar effects
when administered systemically (Figure 5). Responses to IP
injection of IEM-1460 (13.5 mg/kg) generally consisted of a
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FIGURE 5 | Pharmacokinetic analysis and auditory functional measurements
with systemic IEM-1460. (A) After baseline recording, IEM-1460 was injected
(IP, 13.5 mg/kg) at time zero. CAP amplitude measured every 2min for 90 dB
SPL tones at 4, 8, and 13 kHz. At the end of the experiment, perilymph
samples were taken from right (R) and left (L) cochleae before taking the CSF
sample at times indicated. CAP N1-P1 amplitude decreased after drug
injection. (B) Distortion product otoacoustic emissions (2f1-f2) remained stable
after drug injection. (C) Blood plasma levels of IEM-1460 increased to a
sustained maximum within 30min of injection (N = 3 animals). (D) CAP P1
latency was not significantly different (p = 0.421, Wilcoxon, N = 4) after drug
injection (upper) while CAP N1-P1 amplitude was significantly reduced (p <
0.001, Wilcoxon, N = 4) (lower). (E) CAP threshold as a function of cochlear
frequency was not significantly different (p > 0.100 across all frequency
comparisons, Mann-Whitney U, N = 4) before and after systemic injection of
IEM-1460. (F) Perilymph and CSF levels, as % of IEM-1460 concentration in
blood, were not significantly different from each other (p = 0.670; Friedman
test; N = 3). *p < 0.05; ***p < 0.001.
20–50min delay followed by a CAP reduction of 20–50%
from baseline within 10–30min that persisted for up to 2 h
at termination of the experiment (e.g., Figure 5A). Blood was
sampled throughout the experiment and drug levels were
measured using LC/MS. The concentration of IEM-1460 in
blood plasma reached a plateau within ∼30min to a level of
∼7µg/mL, on average, that was maintained for the duration
of the experiment (Figure 5C). Approximately 2 h after IP
injection of IEM-1460, perilymph was collected from the
right and then the left cochlea, followed by collection of
CSF. LC/MS measured perilymph levels at 17–45% of blood
levels, significantly greater than CSF at 8–23% of blood levels
(Figure 5F; p = 0.029, N = 3). Seven µg/mL IEM-1460
corresponds to 23.8µM in blood, and ∼4–11µM of IEM-1460
in perilymph (see Discussion).
To assess the effect of systemic IEM-1460 on cochlear output
(CAP threshold, amplitude, and latency) we compared responses
during stable periods before and after IP injection (i.e., before
and after the delayed reduction in CAP amplitude induced
by the compound). The data were not normally distributed
(Kolmogorov-Smirnov test), thus, the Wilcoxon signed-rank test
was used to compare CAP amplitudes and latencies, before and
after drug injection, in response to tones at different levels for
a given frequency. For all frequencies, the CAP amplitude was
reduced after drug injection, significantly for each tone level
(p < 0.001; Wilcoxon with Bonferroni correction for adjusting
alpha = 0.05/16, N = 4). In the exemplary recording shown in
Figure 5D, lower, the mean difference between pre- and post-
injection CAP amplitudes ranged 19.1–269µV across tone levels.
The differences scaled with tone level, such that the relative
reduction of CAP amplitude was similar (∼50%) for probes
of 40–90 dB SPL. For CAP latency, there was no statistically
significant difference at any tone level (p > 0.100 for all tone
levels; Wilcoxon with Bonferroni correction, N = 4) (Figure 5D,
upper). While CAP amplitude was reduced, distortion product
otoacoustic emissions (DPOAEs) were unaffected (Figure 5B),
suggesting that cochlear mechanics and outer hair cell function
were relatively unaffected by IP injection of 13.5 mg/kg IEM-
1460. CAP thresholds at each frequency tested from 1 to 22 kHz
were not statistically different after IEM-1460 administration
(p > 0.100 across all frequency comparisons; Mann-Whitney
U-test, N = 4; Figure 5E). In conclusion, like cochlear
perfusion (Figure 4), systemic IEM-1460 (Figure 5) reduced
CAP amplitude by as much as 50% with minimal effect on CAP
threshold. In contrast to local delivery, where a 10% increase
in CAP latency was seen with IEM-1460 perfusion, we did not
observe a significant CAP latency shift for systemic dosing.
Systemic IEM-1925 Is Similarly Potent and
Potentially Less Toxic Than IEM-1460
The adamantane derivative IEM-1460 is less potent on CP-
AMPARs than the phencyclidine derivative IEM-1925, but the
two compounds have similar apparent selectivity for CP- over
CI-AMPARs (∼300-fold) (Tikhonov et al., 2000). We asked if
the more potent IEM-1925 could reduce CAP amplitude after
systemic injection, like IEM-1460, at a lower dose. Systemic
delivery of IEM-1925 (8 mg/kg, IP) reduced CAP amplitude to
a similar extent as IEM-1460 (13.5 mg/kg, IP). On average, CAP
amplitude reduction began within 10–15min and was reduced by
∼ 20% after∼1 h (Figure 6A,N= 4 animals per compound). The
CAP amplitude after injection of IEM-1925, similarly to IEM-
1460, was significantly reduced after drug injection for all tone
levels and frequencies (p < 0.001 across all tone levels, Wilcoxon
signed-rank test with Bonferroni correction for adjusting alpha=
0.05/3,N= 4). Blood oxygenation and heart rate were monitored
along with cochlear physiology during the time course of the
experiment. Changes in blood oxygenation were <5% and not
synchronized to drug injection (p = 0.562, Wilcoxon signed-
rank test, N = 4). However, IEM-1460 produced a temporary,
significant reduction in heart rate (Figure 6B) by as much as
15% (p < 0.001, Wilcoxon signed-rank test, N = 4). No such
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FIGURE 6 | Cochlear and cardiopulmonary physiology during systemic
IEM-1460 or IEM-1925. (A) CAP amplitude over time, showing significant
reduction after intraperitoneal (IP) injection of drug (p < 0.001, Wilcoxon,
N = 4). Stimuli were 8 kHz tone bursts at 90 dB SPL. N = 4 animals per
compound. (B) Heart rate and blood oxygen level before and after IP injection
of drug or vehicle control in an exemplary experiment where heart rate was
temporarily reduced by 15% (p < 0.001, Wilcoxon, N = 4) following IP
injection of 13.5 mg/kg IEM-1460 (red trace). (C) CAP threshold as a function
of cochlear frequency was not significantly different after systemic injection of
IEM-1925 (p > 0.100 across all tested frequencies, Mann-Whitney U, N = 4).
reduction in heart rate was observed for IEM-1925. Like IEM-
1460, systemic injection of IEM-1925 had minimal effect on
CAP thresholds (p > 0.100 across all frequency comparisons,
Mann-Whitney U-test, N= 4; Figure 6C).
We tested the metabolic stability of the compounds with in
vitro liver microsome stability assays (Table 1, right). In mouse,
guinea pig, and human liver microsomes, IEM-1460 and IEM-
1925 were very stable, exhibiting half-lives of >300min. We
evaluated the compounds for potential toxicity with assays that
test for inhibition of off-target ion channels and receptors. With
radioligand binding assays, we screened for activity of the test
compounds IEM-1460 and IEM-1925 on a set of ion channels
and receptors to be avoided in the heart and central nervous
system (Table 1, left). Ion channels and ionotropic receptors
included voltage gated KV11.1 (delayed rectifier K+ channel in
cardiomyocytes), the ionotropic NMDAR and AMPAR, and the
nicotinic acetylcholine receptors (AChR) alpha 4/2 and alpha
7. Metabotropic receptors included adenosine, histamine, and
metabotropic AChRs. At a concentration of 1µM, IEM-1460
inhibited radioligand binding to the M4 and M3 AChRs by
37 and 15%, respectively. All other off-target interactions were
inhibited by <5%. For IEM-1925 at 1µM, also, the M4 AChR
was the biggest hit at 19% inhibition. Inhibition of AMPAbinding
to AMPARs by IEM-1925 was 9.5%, while all other competitive
binding interactions were inhibited by<5% (Table 1). This panel
of off-target binding assays suggests that IEM-1925 may have an
enhanced safety profile relative to IEM-1460.
DISCUSSION
Antagonizing CP-AMPARs to Prevent
Glutamate Excitotoxicity?
Ischemia, noise exposure, or perfusion of the guinea pig cochlea
with glutamate, kainate, or the specific agonist AMPA produces
osmotic swelling of ANF postsynaptic terminals in the organ
of Corti underneath IHCs (Puel et al., 1994, 1998; Figure 3).
Landmark studies used electron microscopy after perfusion
of glutamate receptor agonists and antagonists into the basal
cochlear turn. These chemical lesion experiments showed that
ANF terminal swelling was prevented by pre-perfusion with
DNQX, a pan-AMPAR antagonist, but not with the N-methyl-D-
aspartate receptor (NMDAR) antagonist D-AP5, demonstrating
that glutamatergic excitotoxicity is mediated via AMPARs (Puel
et al., 1994). AMPAR agonists bring positive ions into the
ANF terminal and dendrite. The resulting depolarization of
the nearby heminode triggers additional Na+ influx into the
thin fiber through voltage-gated channels. The spike-generating
heminodes are located at the habenula perforata (HP), just
before the myelin begins, where ANFs enter the osseous spiral
lamina (OSL; Figures 1B,C). These myelinated peripheral axons
propagate spikes toward bipolar cell bodies in the spiral ganglion.
Unlike a conventional neuron, the spike-generating heminode of
the ANF is separated from the excitatory ribbon synapse not by
a cell body but instead by only a∼20µm length of dendrite with
submicron diameter (Figures 1B,C). The tight anatomical and
electrical coupling between the synapse and spike generator, as
well as the alignment of heminodes at the HP where the myelin
begins, is important for synchronous activation of ANFs in
response to sound (Rutherford et al., 2012; Kim and Rutherford,
2016; Wan and Corfas, 2017). This may also render the ANF
dendrite vulnerable during high rates of activity, when influx
of positive ions at the synapse and heminode leads to osmotic
terminal swelling and synapse disintegration.
AMPARs mediate most of the fast excitatory chemical
transmission in the brain. As GluA2 is the 1st or 2nd most
abundant subunit, the great majority of AMPAR tetramers
are thought to include at least one GluA2 subunit, >99%
of which are Q/R edited at a critical residue in the pore’s
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TABLE 1 | In vitro off-target binding assays and metabolic stability of IEM-1460 and IEM-1925.




Receptor/Channel Mean% inhibition (N = 2) Mean% inhibition (N = 2) Mean (N = 2)
hERG potassium (Kv 11.1), human <1 <5
NMDA glutamate, rat <1 <1 Human
AMPA glutamate (GluA2-containing), rat 9.5 <1 IEM-1460
IEM-1925
>300
>300A1 adenosine GPCR, human <1 <1
H1 histamine GPCR, human <1 <1 Guinea pig
H2 histamine GPCR, human <1 <1 IEM-1460
IEM-1925
>300
>300H3 histamine GPCR, human <5 <1
H4 histamine GPCR, human <5 <1
M1 acetylcholine GPCR, human <1 <1 Mouse
M2 acetylcholine GPCR, human <1 <1 IEM-1460
IEM-1925
>300
>300M3 acetylcholine GPCR, human <5 15
M4 acetylcholine GPCR, human 19 37
M5 acetylcholine GPCR, human <5 5.2
nAChR alpha4/beta2, human <1 <1
nAChR alpha7, human <2 <1
Left: Radioligand binding assays show% inhibition of binding of the receptor-specific radioligand (see Methods) to the off-target ion channel or receptor by 1µM IEM-1460 or IEM-1925.
Right: Stability of 1µM IEM-1460 or IEM-1925 in the presence of mouse, guinea pig, or human liver microsomes at 37◦C.
selectivity filter to reduce overall channel conductance and
relative Ca2+ permeability (Geiger et al., 1995; Schwenk et al.,
2012; Shanks et al., 2012; Wright and Vissel, 2012). Thus,
AMPARs are generally of the relatively low-conductance variety
and impermeable to Ca2+ due to inclusion of edited GluA2
in the tetramer. An exception to this general rule are some
neurons in the ascending auditory pathway, where synapses
with fast kinetics of transmission support rapid and precise
signaling of auditory information using AMPARs that appear
to rely mainly on GluA3 and GluA4 (Otis et al., 1995; Yang
et al., 2011; Rubio et al., 2017; Lujan et al., 2019). Absence
of GluA2 in the tetramer results in an AMPAR with larger
currents, faster kinetics, and greater permeability to Ca2+.
While some synaptic mechanisms appear to utilize CP-AMPARs,
aberrant expression of CP-AMPARs has been implicated in
many neurological disorders where excessive activity leads to
neurodegeneration (Weiss, 2011), including but not limited to
epilepsy (Grooms et al., 2000; Rajasekaran et al., 2012; Malkin
et al., 2016), ischemia (Kwak and Weiss, 2006), traumatic brain
injury (Spaethling et al., 2008), and illicit substance addiction and
withdrawal (Pistillo et al., 2016; Wolf, 2016). The in vitro binding
assays (Table 1) suggest that CNS toxicity of IEM-1925 may be
limited based on weak interference of binding of CNS receptors
to their natural ligands. However, subsequent studies of IEM-
1925 or its derivatives must evaluate binding to the pore of off-
target channels. It will be imperative to thoroughly evaluate CNS
toxicity of any drug candidates with behavioral studies as well.
The fish lateral-line organ and the mammalian organ of
Corti are examples of peripheral sensory organs that mediate
fast acoustic signals via synapses between sensory hair cells and
primary afferent neurons which appear to utilize GluA2-lacking,
CP-AMPARs (Sebe et al., 2017; Hu et al., 2020). The faster, larger
currents of CP-AMPARs are expected to drive the postsynaptic
neuron to spike threshold more precisely with respect to
temporal changes in the hair cell receptor potential, which
may be important for mechanisms of sensory encoding such as
sound source localization in the horizontal plane mediated by
phase-locking (Goutman, 2012; Rutherford et al., 2012, 2021;
Li et al., 2014). In fish and mammals, excessive activation of
AMPARs can lead to postsynaptic terminal swelling and synaptic
disintegration, suggesting that CP-AMPARs may be targeted
for prevention of glutamatergic excitotoxic damage. Indeed,
local delivery of the CP-AMPAR antagonist IEM-1460 prevented
damage induced by chemical lesion or acoustic trauma (Sebe
et al., 2017; Hu et al., 2020). However, the selectivity of IEM-
1460 for CP-AMPARs is concentration dependent (Tikhonov
et al., 2000). At high concentration it will block all AMPARs
thus preventing all auditory nerve activity and hearing itself, as
demonstrated by perfusion of different drug concentrations into
scala tympani (Figure 4A). For prevention of damage to hearing,
local delivery of therapeutic agents to the inner ear is likely too
invasive. Therefore, here we asked if systemic administration
of CP-AMPAR antagonists could safely reduce afferent synaptic
activity in the inner ear without elevating auditory thresholds.
We further asked if the level of drug in perilymph was consistent
with selective blockade of CP-AMPARs.
Reduction of Auditory Nerve Activity
Without Elevation of Hearing Threshold
We found that systemic administration of the CP-AMPAR
antagonists IEM-1460 or IEM-1925 reduced CAP amplitude
(Figures 5A,D, 6A) without significantly affecting auditory
thresholds (CAP audiogram, Figures 5E, 6C) or otoacoustic
emissions (i.e., DPOAEs, Figure 5B). Local or systemic dosing
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of IEM-1460 attenuated CAP amplitudes in response to low-
level and high-level tones (Figure 4D). In contrast, the medial
olivocochlear (MOC) efferent reflex inhibits the CAP primarily
in response to low-level sounds and is thus thought to provide
only limited protection against acoustic trauma (Puria et al.,
1996; Guinan, 2006; Lichtenhan et al., 2016b). While middle ear
muscle reflexes are activated at high sound levels and protectively
attenuate sound transmission through the middle ear, these
muscles fatigue over prolonged exposure and have a long latency
(i.e., 10–15ms) that does not seem to protect against sudden
loud sounds or prolonged exposure (Simmons, 1960; Ryan et al.,
1994). Attenuation of the CAP at high sound levels, as seen here
with antagonism of CP-AMPARs, could be protective when the
MOC or middle ear reflexes are ineffective.
In animal models, noise exposure can permanently change
cochlear physiology in part through effects on synapses that don’t
necessarily cause an immediate permanent threshold shift but do
reduce CAP or wave-I amplitude. Such effects of noise whichmay
be compounded by aging have been termed “hidden hearing loss”
because they aren’t detected by pure-tone audiometry (Liberman,
2020). Data from audiometrically normal adults shows that
people with smaller auditory nerve or subcortical responses
perform relatively poorly on hearing speech in the presence of
background noise (Bharadwaj et al., 2015; Bramhall et al., 2015;
Stamper and Johnson, 2015; Grant et al., 2020). However, this
is still controversial as many studies in humans have failed to
find significant relationships between speech perception and the
amplitude of the auditory nerve action potential (Prendergast
et al., 2017; Guest et al., 2018; for review see Bramhall et al.,
2019). An outstanding question is if pharmacologic reduction
of auditory nerve activity, without threshold elevation, reduces
intelligibility of speech and other sounds. If not, then it may
be possible to protect hearing by dampening activity without
compromising hearing function. If sound intelligibility is reduced
during protection, the benefits of protection may outweigh
the disadvantage of temporarily reduced audibility. Subsequent
studies should evaluate the time course of reduced auditory nerve
activity after systemic administration, as the current studies were
terminated before the effect wore off.
Relationship Between CP-AMPARs and
ANF Physiology
Each cochlear afferent synapse has a relatively large PSD,
parts of which appear to lack GluA2 based on subunit-specific
pharmacology and microscopy (Sebe et al., 2017; Hu et al., 2020).
In mouse, after ∼2.5 days of sustained intracochlear delivery of
IEM-1460, Hu et al. (2020) found prevention of synapse loss
following exposure to synaptopathic noise. Interestingly, IEM-
1460 prevented synapse loss and loss of wave-I amplitude without
significantly reducing wave-I amplitude during the protection.
This suggested that GluA2-containing AMPARs can mediate
hearing function without reduction of auditory nerve activity
alongside chronic, protective antagonism of GluA2-lacking CP-
AMPARs. Here, acute local or systemic drug delivery reduced
sound-evoked activity (i.e., the CAP amplitude) when IEM-
1460 was delivered at concentrations selective for CP-AMPARs
(Figures 4–6). This is somewhat surprising, given the lack of ABR
wave-I reduction during protection in Hu et al. (2020).
To explain the difference between the present findings and
those in Hu et al. (2020), specifically the effect of IEM-1460 on
suprathreshold hearing, one possibility is a species difference.
If the guinea pig cochlea has more CP-AMPARs, and thus
more block of transmission by CP-AMPAR antagonists, then
IEM-1460 may reduce ANF activity in the guinea pig and
not the mouse. A 2nd possibility is the effect of chronic
vs. acute drug delivery. If synaptic adaptation compensated
during chronic dosing by inserting more GluA2-containing, CI-
AMPARs that are insensitive to IEM-1460, then ABR wave-
I (or CAP) amplitudes may have been maintained in the
continuous presence of the drug. A 3rd possibility is a difference
in the concentration of compound between experiments. In
Hu et al. (2020) the concentration of drug in perilymph was
unknown as a minipump was used to elute the compound
into scala tympani. In the present study, drug concentration
was controlled by local perfusion of known concentrations
into scala tympani (Figure 4) or by measuring concentrations
in cochlear fluid samples (Figure 5). If the concentration was
considerably lower in the minipump experiment, this could
explain the lack of wave-I reduction. We find this possibility
unlikely because a well-established simulation model of drug
concentration in scala tympani of the mouse suggested a
mean concentration of ∼ 58µM (https://alecsalt.com/index.
php/simulations/fluidsim4). A fourth consideration is different
anesthesia. Here we used isoflurane, whereas Hu et al. (2020)
used ketamine/xylazine.
A separate question is: how were the mouse synapses
protected in the absence of reduced ABR wave-I during chronic
presence of the drug (Hu et al., 2020)? Subunit adaptation may
have resulted in fewer CP-AMPARs, in which case less Ca2+ entry
relative to Na+ entry could reduce noise-induced excitotoxicity.
As well, if the ANF EPSC is much larger than required to
reach spike threshold, as suggested by ex vivo electrophysiology
(Rutherford et al., 2012), then the excitotoxic EPSCmay be safely
reduced in level without inhibiting action potential generation. In
this scenario, the number of active ANFs would not be reduced,
but the smaller EPSC may increase spike latency. Interestingly,
CAP latency was slightly increased with local delivery of IEM-
1460 in guinea pig (Figure 4D), although not significantly for
systemic delivery (Figure 5D).
A Mixture of Ca2+-Permeable and
Ca2+-Impermeable AMPARs at the Hair
Cell Afferent Synapse
Tight spatial coupling between the ribbon synapse and spike-
generating heminode (Figure 1), along with small fiber diameter
and high rates of activity, results in ANF dendritic vulnerability
to osmotic imbalance that may be exacerbated by the presence
of CP-AMPARs. The larger Na+ and Ca2+ currents through
CP-AMPARs, while presumably important for fast signaling,
also place greater metabolic demands on the ANF through
energy consumption by the pumps that maintain ionic gradients.
The Na+/K+-ATPase on the ANF plasma membrane (labeling
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ANFs in Figures 1C, 3, abbreviated NKA) uses energy to pump
Na+ out of the cytoplasm (Chow and Forte, 1995; Blanco
and Mercer, 1998). Calcium is particularly expensive to handle.
The Na+/Ca2+ exchanger is an antiporter membrane protein
that removes Ca2+ from cells by allowing Na+ to flow into
cells. A single Ca2+ ion is exported for the import of three
Na+ ions (Fettiplace and Nam, 2019) which must then be
pumped out by the Na+/K+-ATPase. We suggest this is one way
that excessive activity of CP-AMPARs produces oxidative stress
through energy consumption.
In rat hippocampus, on non-pyramidal cells (expressing
mainly GluA2-lacking CP-AMPARs) the IC50 for IEM-1460 and
IEM-1925 is ∼3 and ∼1µM, respectively, while on pyramidal
cells (expressing mainly GluA2-containing CI-AMPARs) the
IC50 is > 500 and > 200µM, respectively (Tikhonov et al.,
2000). Here, in guinea pig, with CAP measurements during
measured or defined concentrations of the compounds in
perilymph, we found reduction of ANF activity at concentrations
consistent with the presence of a mixture of CP- and CI-
AMPARs. Figure 5C shows that IEM-1460 was sustained in
blood at ∼7µg/mL, on average after IP injection. Figure 5F
shows that perilymph levels were ∼30% of blood levels. IEM-
1460 at 2µg/mL is ∼7µM, near to the IC50 for CP-AMPARs
but far from the IC50 for CI-AMPARs. This level of systemic
dosing reduced the CAP by ∼20%, on average, consistent with
the presence of CP-AMPARs. In other experiments, cochlear
perfusion of nominally 100µM IEM-1460 (Figure 4) reduced
CAP amplitude by ∼55%. This concentration is still well below
the IC50 for CI-AMPARs (>500µM), and well above the IC50
for CP-AMPARs (∼3µM). Taken together, we conclude that
afferent synapses in the guinea pig cochlea contain a mixture of
CP- and CI-AMPARs, as in the mouse (Hu et al., 2020). It will
be important to test this directly with patch-clamp recordings
of EPSCs from ANF postsynaptic terminals in the cochlea, in
subsequent studies.
Physicochemical Properties of IEM-1460
and IEM-1925 for Oral Bioavailability and
Inner Ear Permeation
There are currently no FDA-approved drugs for prevention
of noise-induced hearing loss or other noise-induced hearing
disorders. A limited understanding of unique targets within
the inner ear hinders drug design for systemic delivery, thus
much of current focus has been on local delivery (McCall et al.,
2010; Nyberg et al., 2019). Unfortunately, intracochlear delivery
(i.e., directly to the inner ear) is too invasive for chronic or
sub-chronic dosing for prevention of damage to healthy ears.
Middle ear delivery may introduce drugs into the cochlea if
they permeate the round window into scala tympani, however,
infiltration of CSF into perilymph at the base of the cochlea
near the round window prevents drugs from making it very
FIGURE 7 | Molecular structures and CNS accessibilities of AMPAR antagonists (rectangles). (A) The agonists glutamate and GABA are small but not very lipophilic.
CNQX, DNQX, and NBQX are competitive AMPAR antagonists likely too polar to pass the gut. Perampanel, GYKI-52466, and GYKI-53655 are non-competitive and
non-selective AMPAR antagonists that function as negative allosteric modulators. IEM-1460, IEM-1925, NASPM, and PhTx-74 are non-competitive and selective
CP-AMPAR antagonists that function as open-channel pore blockers. (B) The so-called “boiled egg plot” uses a hydrophilicity metric developed by Wildman and
Crippen (Y-axis, WLogP) and topological polar surface area (X-axis, tPSA) to predict gastrointestinal absorption and brain penetration. Egg-white region: high
probability of absorption by the gastrointestinal tract; Egg-yolk region: highest probability of permeation through the blood-brain barrier (BBB). The drugs Perampanel
and Diazepam are well within the egg yolk. Glutamate and GABA, although made in the brain, are predicted not to penetrate the BBB. IEM-1460 and IEM-1925 are
less potent than NASPM and PhTx-74 (µM vs. nM potency) but more likely to permeate the CNS.
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far up the cochlea resulting in a gradient from base to apex
in guinea pig that effectively limits drug delivery to the base.
When drugs enter the cochlea through blood, there is no
such gradient. For systemic dosing, a favorable inner ear drug
candidate would target a specific receptor within the inner ear
with limited CNS expression, while reaching the inner ear at
efficacious concentrations.
The data in this study show that IEM-1460 and IEM-1925
may have favorable pharmacokinetic properties for targeting CP-
AMPARs in the inner ear with systemic dosing (Figures 5C,F),
and that IEM-1925 may be less toxic than IEM-1460 (Figure 6B;
Table 1). Based on their computed hydrophilicity (CLogP or
WLogP, Wildman and Crippen, 1999) and polarity (tPSA),
IEM-1460 and IEM-1925 are predicted to be absorbed by
the gastrointestinal tract and cross the blood brain barrier
(BBB) (Figure 7). In Figure 7B, the egg-white region is the
physicochemical space of molecules with highest probability of
being absorbed by the gastrointestinal tract, and the egg-yolk
region is the physicochemical space of molecules with highest
probability to further permeate into the brain (Zoete et al., 2016;
Daina et al., 2017). Like the non-selective AMPAR antagonists
Perampanel and GYKI-52466, the selective IEM-1460 and IEM-
1925 are in the egg-yolk (i.e., predicted to cross the BBB). These
compounds are non-competitive AMPAR antagonists, meaning
they don’t compete for glutamate’s binding site on the ligand-
binding domains of other glutamate receptors. Instead, they
inhibit by blocking the ion channel pore. Unlike Perampanel and
GYKI-52466, IEM-1460 and IEM-1925 are selective for GluA2-
lacking AMPARs, restricting their activity to CP-AMPARs. In
addition, IEM-1460 and IEM-1925 are open-channel blockers,
meaning the channel must open before it can be accessed by the
antagonists. Non-competitive, open-channel antagonists block
slowly such that the initial component of the response may
be weakly affected. They require the channel to spend time in
the open conformation for blockade to develop, and thus they
should be more effective at blocking AMPAR channels that are
stimulated at high frequency. By selectively targeting the most
frequently active GluA2-lacking AMPARs, it may be possible to
inhibit excitotoxicity more so than normal synapse function.
The mechanism by which compounds enter perilymph is
not clear. Compounds that penetrate the BBB can potentially
enter perilymph via the cochlear aqueduct, neuronal pathways,
or lymphatic pathways (Salt and Hirose, 2018). The blood-
labyrinth barrier (BLB) regulates the chemical composition of
endolymph and perilymph via the stria vascularis and spiral
ligament (Juhn and Rybak, 1981; Suzuki et al., 2002). It has
been hypothesized through experiments in guinea pigs that noise
exposure may increase macromolecular transport in the stria
vascularis such that systemically administered macromolecules
can be more readily transported into the inner ear by noise
exposure (Suzuki et al., 2002). This phenomenon can potentially
be used for drug design and targeting. The BLB may be leakier
than the BBB, in general (Hirose et al., 2014; Wu et al., 2014).
After systemic injection of IEM-1460, perilymph levels trended
somewhat higher than CSF levels (Figure 5F). Nonetheless, for
an oral drug the challenge will be to find compounds without
significant CNS side effects. Although IEM-1925 (8 mg/kg)
produced similar CAP reduction as IEM-1460 (13.5 mg/kg),
LC/MS did not detect significant IEM-1925 in perilymph or CSF.
Very low levels of IEM-1925 were detected in blood, despite
successful calibration of concentrations in artificial perilymph
and blood plasma (Figure 2), suggesting the IEM-1925 may have
been metabolized, bound to tissue, or otherwise masked in vivo.
Both compounds had very long half-lives in liver microsome
stability assays (Table 1), suggesting IEM-1925 metabolism in
the guinea pig that was not accounted for in liver microsomes.
Future studies should investigate candidate metabolites with
activity at CP-AMPARs. Analysis of our PK data from Figure 5C
estimates an elimination half-life of 118min for IEM-1460 in
blood. Although levels of IEM-1925 in blood were low, we were
still able to estimate a half-life of 68min. Subsequent studies
will measure the recovery of CAP amplitudes in the hours after
drug administration.
In addition to CLogP and tPSA, other molecular properties
important for a drug’s pharmacokinetics in the human body
including their absorption, distribution, metabolism, and
excretion (ADME) are molecular weight (MW), acidity (pKa),
number of hydrogen bond donors (HB-donor) and acceptors
(HB-acceptor), and the number of rotatable bonds (Table 2).
Lipinski’s rule of five, also called Pfizer’s rule of five, is a
rule of thumb to determine how likely a compound is to be
an orally active drug in humans (Lipinski et al., 2001). The
rule states that there should be no more than five hydrogen
bond donors, no more than 10 hydrogen bond acceptors,
TABLE 2 | Physicochemical properties for drug-likeness.
Name Computed property
MW CLogP pKa HB-donor HB-acceptor Polar surface area Rotatable bonds
Lipinski (oral) <500 ≤5 3–10 ≤5 ≤10 ≤140 ≤14
CNS bioavailability ≤400 ≤4 7.5–10 ≤3 ≤7 ≤60 ≤8
PhTX-74 449 3.3 9.8 7 6 116 19
IEM-1460 294 3.7 10.5 1 2 12 8
IEM-1925 260 3.7 10.5 3 2 38 7
Physicochemical properties were computed for IEM-1460, IEM-1925, and philanthotoxin 74 (PhTX-74). They are compared with the Lipinski rules of thumb for oral absorption and
CNS bioavailability.
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a MW < 500 Daltons, and CLogP < 5. Table 2 shows that
IEM-1460 and IEM-1925 have good physicochemical properties
for drug-likeness.
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